CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
E4599 | ECOG | Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC | Adult CIRB - Late Phase Emphasis | Completed |
NRG-CC003 | NRG | Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer | Cancer Prevention and Control CIRB | Available to Open |
NRG-HN009 | NRG | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-HN004 | NRG | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-HN006 | NRG | Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
GOG-0263 | GOG | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk; Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
EA5182 | ECOG-ACRIN | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-GI001 | NRG | Randomized Phase III Study of Focal Radiation Therapy for Unresectable; Localized Intrahepatic Cholangiocarcinoma | Adult CIRB - Late Phase Emphasis | Completed |
E5508 | ECOG | Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
RTOG-1112 | RTOG | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |